Patents by Inventor David M. Jablons

David M. Jablons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-cancer/anti-fibrosis compounds
    Patent number: 11932606
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 19, 2024
    Assignee: The Regents of the University of California
    Inventors: David M. Jablons, Wei Xu, Liang You, Shu Liu, Shendong Yuan, Sunghoon Ma, Morrison Mac
  • Anti-Cancer/Anti-Fibrosis Compounds
    Publication number: 20230192621
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 31, 2018
    Publication date: June 22, 2023
    Inventors: David M. JABLONS, Wei XU, Liang YOU, Shu LIU, Shendong YUAN, Sunghoon MA, Morrison MAC
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20230150942
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Application
    Filed: December 5, 2022
    Publication date: May 18, 2023
    Inventors: Csaba PETO, Bhairavi TOLANI, Gavitt WOODARD, Tsze TSANG, Michael MANN, David M. JABLONS, Biao HE
  • Compounds and compositions for the treatment of cancer
    Patent number: 11560356
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 24, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, RESCUE THERAPEUTICS, INC.
    Inventors: Csaba Peto, Bhairavi Tolani, Gavitt Woodard, Tsze Tsang, Michael Mann, David M. Jablons, Biao He
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20220402894
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 15, 2021
    Publication date: December 22, 2022
    Inventors: Csaba J. PETO, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Antibodies specific to Sonic Hedgehog and method of use thereof
    Patent number: 11479601
    Abstract: Antibodies that specifically bind to a Sonic Hedgehog (Shh) polypeptide, or an antigen binding fragment thereof, are provided. Also provided are methods of treating an individual for cancer using the Shh polypeptide antibodies. Methods of analyzing a tissue sample for cell-surface expression of a full-length Shh polypeptide are also provided.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: October 25, 2022
    Assignee: The Regents of the University of California
    Inventors: David M. Jablons, Bhairavi Tolani, Biao He, Etienne Giroux-Leprieur
  • MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER
    Publication number: 20220195532
    Abstract: The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 23, 2022
    Inventors: David M. JABLONS, Dan J. RAZ, Biao HE
  • Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
    Patent number: 11072600
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: July 27, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ATLASMEDX, INC.
    Inventors: Csaba J. Peto, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Compounds and Compositions for the Treatment of Cancer
    Publication number: 20210009523
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 14, 2021
    Inventors: Csaba Peto, Bhairavi Tolani, Gavitt Woodard, Tsze Tsang, Michael Mann, David M. Jablons, Biao He
  • MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER
    Publication number: 20200377957
    Abstract: The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.
    Type: Application
    Filed: December 23, 2019
    Publication date: December 3, 2020
    Inventors: David M. JABLONS, Dan J. RAZ, Biao HE
  • Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
    Patent number: 10640493
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 5, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ATLASMEDX, INC.
    Inventors: Csaba J. Peto, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20190352283
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 21, 2019
    Inventors: Csaba J. PETO, David M. JABLONS, Tsze TSANG, Hassan LEMJABBAR-ALAOUI
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20190337928
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 7, 2019
    Inventors: Csaba J. PETO, David M. JABLONS, Tsze TSANG, Hassan LEMJABBAR-ALAOUI
  • Antibodies Specific to Sonic Hedgehog and Method of Use Thereof
    Publication number: 20190161538
    Abstract: Antibodies that specifically bind to a Sonic Hedgehog (Shh) polypeptide, or an antigen binding fragment thereof, are provided. Also provided are methods of treating an individual for cancer using the Shh polypeptide antibodies. Methods of analyzing a tissue sample for cell-surface expression of a full-length Shh polypeptide are also provided.
    Type: Application
    Filed: June 28, 2017
    Publication date: May 30, 2019
    Applicant: The Regents of the University of California
    Inventors: David M. Jablons, Bhairavi Tolani, Biao He, Etienne Giroux-Leprieur
  • MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER
    Publication number: 20180002761
    Abstract: The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.
    Type: Application
    Filed: March 8, 2017
    Publication date: January 4, 2018
    Inventors: David M. JABLONS, Dan J. RAZ, Biao HE
  • Targeting GLI proteins in human cancer by small molecules
    Patent number: 9840470
    Abstract: The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: December 12, 2017
    Assignee: The Regents of the University of California
    Inventors: Biao He, Michael Mann, David M. Jablons
  • Multigene prognostic assay for lung cancer
    Patent number: 9476098
    Abstract: The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 25, 2016
    Assignees: The Regents of the University of California, Encore Clinical, Inc.
    Inventors: Michael J. Mann, David M. Jablons, Johannes Kratz, David M. Berryman
  • Targeting GLI proteins in human cancer by small molecules
    Patent number: 9370521
    Abstract: The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: June 21, 2016
    Assignee: The Regents of the University of California
    Inventors: Biao He, Michael Mann, David M. Jablons
  • EMX2 in cancer diagnosis and prognosis
    Patent number: 9279157
    Abstract: The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: March 8, 2016
    Assignee: The Regents of the University of California
    Inventors: Biao He, David M. Jablons
  • Milk bottle
    Patent number: D832713
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: November 6, 2018
    Assignee: CAL PHRESH, LLC
    Inventors: Michael J. Mann, David M. Jablons, Hans Baldauf, Christian Von Eckartsberg